Vertex Pharmaceuticals (LTS:0QZU) Cyclically Adjusted Revenue per Share: $32.15 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QZU Vertex Pharmaceuticals Inc LTS:0QZU
94 GF Score
Price $525.78
GF Value $520.71
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share?

Vertex Pharmaceuticals LTS:0QZU -1.03% 94 Cyclically Adjusted Revenue per Share is $32.15 as of Jun. 2026. GuruFocus rates LTS:0QZU with a GF Score™ of 94/100 and a GF Value™ of $520.71 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was $13.064. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $32.15 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 18.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 21.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 25.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vertex Pharmaceuticals was 29.90% per year. The lowest was -4.70% per year. And the median was 16.05% per year.

As of today (2026-08-13), Vertex Pharmaceuticals's current stock price is $525.78. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $32.15. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 16.35.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.11.


Vertex Pharmaceuticals  (LTS:0QZU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=525.78/32.15
=16.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.89 15.96 19.82 24.26 29.21

Vertex Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.85 27.97 29.21 30.55 32.15

LTS:0QZU vs REGN, RVMD, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


LTS:0QZU
94GF Score
Vertex Pharmaceuticals Inc LTS:0QZU
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.064/333.9520*333.9520
=13.064

Current CPI (Jun. 2026) = 333.9520.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.689 241.428 2.336
201612 1.871 241.432 2.588
201703 2.874 243.801 3.937
201706 2.162 244.955 2.947
201709 2.310 246.819 3.125
201712 2.539 246.524 3.439
201803 2.479 249.554 3.317
201806 2.909 251.989 3.855
201809 3.020 252.439 3.995
201812 3.349 251.233 4.452
201903 3.299 254.202 4.334
201906 3.623 256.143 4.724
201909 3.647 256.759 4.743
201912 5.389 256.974 7.003
202003 5.750 258.115 7.439
202006 5.788 257.797 7.498
202009 5.825 260.280 7.474
202012 6.225 260.474 7.981
202103 6.584 264.877 8.301
202106 6.871 271.696 8.445
202109 7.640 274.310 9.301
202112 8.068 278.802 9.664
202203 8.133 287.504 9.447
202206 8.489 296.311 9.567
202209 8.995 296.808 10.121
202212 8.846 296.797 9.953
202303 9.123 301.836 10.094
202306 9.575 305.109 10.480
202309 9.530 307.789 10.340
202312 9.654 306.746 10.510
202403 10.305 312.332 11.018
202406 10.250 314.175 10.895
202409 10.620 315.301 11.248
202412 11.318 315.605 11.976
202503 10.675 319.799 11.147
202506 11.451 322.561 11.855
202509 11.943 324.800 12.280
202512 12.451 324.054 12.831
202603 11.654 330.213 11.786
202606 13.064 333.952 13.064

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $32.15 mean?
Vertex Pharmaceuticals (LTS:0QZU) has a Cyclically Adjusted Revenue per Share of $32.15 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Vertex Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $32.15. Overall, Vertex Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to REGN and RVMD?
Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share of $32.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $32.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (LTS:0QZU) is currently considered Fairly Valued. The stock's GF Value™ is $520.71, compared to a current price of $525.78 — trading 1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $32.15. Vertex Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (LTS:0QZU), the current Cyclically Adjusted Revenue per Share is $32.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (LTS:0QZU) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued. The current stock price of $525.78 is trading 1% above its estimated GF Value™ of $520.71. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0QZU:

  • Cyclically Adjusted Revenue per Share: $32.15
  • GF Value™: $520.71 vs. price of $525.78 (1% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the LTS:0QZU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
94GF Score

Get the complete analysis for LTS:0QZU

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$525.78
Price
$520.71
GF Value